Otsuka Slaps Amneal With IP Suit Over Generic Abilify

Law360, New York (April 27, 2012, 8:13 PM EDT) -- Japanese drugmaker Otsuka Pharmaceuticals Co. Ltd. on Thursday launched a patent infringement suit against Amneal Pharmaceuticals LLC, challenging the rival's attempt to score U.S. approval of a generic version of anti-psychotic drug Abilify.

In a complaint filed in New Jersey federal court, Otsuka argued that Amneal and two of its affiliates, including one in India, had infringed its patent by submitting an Abbreviated New Drug Application to the U.S. Food and Drug Administration.

"Amneal has infringed at least one claim of the '257 patent by submitting,...
To view the full article, register now.